154 related articles for article (PubMed ID: 34591259)
21. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
[TBL] [Abstract][Full Text] [Related]
22. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
Castañeda-Orjuela C; De la Hoz-Restrepo F
Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049
[TBL] [Abstract][Full Text] [Related]
23. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
Ayieko P; Griffiths UK; Ndiritu M; Moisi J; Mugoya IK; Kamau T; English M; Scott JA
PLoS One; 2013; 8(6):e67324. PubMed ID: 23826268
[TBL] [Abstract][Full Text] [Related]
24. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
Vaccine; 2024 Jun; ():. PubMed ID: 38879409
[TBL] [Abstract][Full Text] [Related]
26. Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.
Wilson M; McDade C; Beby-Heijtel AT; Waterval-Overbeek A; Sundaram V; Perdrizet J
Infect Dis Ther; 2023 Jul; 12(7):1809-1821. PubMed ID: 37318710
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
28. Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis.
Lai X; Garcia C; Wu D; Knoll MD; Zhang H; Xu T; Jing R; Yin Z; Wahl B; Fang H
Lancet Reg Health West Pac; 2023 Mar; 32():100666. PubMed ID: 36785861
[TBL] [Abstract][Full Text] [Related]
29. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
[TBL] [Abstract][Full Text] [Related]
30. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
Pugh S; Wasserman M; Moffatt M; Marques S; Reyes JM; Prieto VA; Reijnders D; Rozenbaum MH; Laine J; Åhman H; Farkouh R
Infect Dis Ther; 2020 Jun; 9(2):305-324. PubMed ID: 32096144
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
Wang XJ; Saha A; Zhang XH
Cost Eff Resour Alloc; 2017; 15():17. PubMed ID: 28852326
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children.
Mezones-Holguín E; Bolaños-Díaz R; Fiestas V; Sanabria C; Gutiérrez-Aguado A; Fiestas F; Suárez VJ; Rodriguez-Morales AJ; Hernández AV
J Infect Dev Ctries; 2014 Dec; 8(12):1552-62. PubMed ID: 25500653
[TBL] [Abstract][Full Text] [Related]
34. Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective.
Li X; Warren S; Rozenbaum MH; Perdrizet J
Infect Dis Ther; 2023 Mar; 12(3):997-1006. PubMed ID: 36867396
[TBL] [Abstract][Full Text] [Related]
35. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.
Sevilla JP; Burnes D; El Saie RZ; Haridy H; Wasserman M; Pugh S; Perdrizet J; Bloom D
Hum Vaccin Immunother; 2022 Nov; 18(6):2114252. PubMed ID: 36070504
[TBL] [Abstract][Full Text] [Related]
39. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]